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ABSTRACT
Objectives: Low serum amylase (LSA) was reported
to be associated with obesity, metabolic syndrome
(MetS) and diabetes. However, it is unknown as to
whether LSA is associated with non-alcoholic fatty liver
disease (NAFLD), a hepatic manifestation of MetS and
insulin resistance. Therefore, we performed a clinical
epidemiological study to investigate this potential
association.
Design: A cross-sectional observational study with
multivariate analysis.
Setting: Subjects were recruited in a healthcare centre
in Saitama, an eastern district of Japan, near Tokyo.
Participants: A total of 1475 asymptomatic adults
aged 30–79 years who underwent detailed medical
check-ups and who regularly consumed small amounts
of alcohol (<20 g/day).
Outcome measures: Serum amylase,
cardiometabolic risk factors, NAFLD determined by
ultrasound, MetS determined by Adult Treatment
Panel-III criteria and diabetes were assessed.
Results: The prevalence of NAFLD increased
significantly from 22.5% to 42.4% (all grades) and
from 9.2% to 24.0% (moderate or severe grade) from
the highest to the lowest quartile of serum amylase.
Multiple logistic regression analysis showed that,
compared with the highest quartile of serum amylase,
the lowest quartile of serum amylase was significantly
associated with any-grade NAFLD and with moderate-
to-severe NAFLD, even after adjusting for MetS or
diabetes. The association between LSA and any-grade
NAFLD disappeared after further adjustment for body
mass index or waist circumference, whereas the
association between LSA and moderate or severe
NAFLD remained statistically significant (ORs (95%CI),
2.01 (1.07 to 3.78) and 2.06 (1.09 to 3.87),
respectively, both p=0.01).
Conclusions: Our results suggest that LSA may be
associated with moderate or severe NAFLD in
asymptomatic adults independent of MetS, diabetes
and obesity. These results warrant confirmation in
further studies.
INTRODUCTION
Abnormal serum amylase levels generally
reﬂect the overall dysfunction of the pan-
creas or salivary glands. Although the clinical
relevance of elevated serum amylase levels
has been extensively studied in relation to
various conditions, including acute pancrea-
titis, pancreatic cancer, ectopic amylase-
producing tumours, abdominal trauma and
kidney dysfunction,1–5 the clinical relevance
of low serum amylase (LSA) has not been
examined. LSA is conventionally considered
as a crude marker for diffuse pancreas
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destruction secondary to pancreatic diseases, such as
advanced chronic pancreatitis and cystic ﬁbrosis.6 7 LSA
or low pancreatic amylase is also associated with insulin
deﬁciency in patients with type 1 diabetes and in
patients with longstanding type 2 diabetes.8–11 In our
recent community-based study, LSA, deﬁned as a serum
amylase concentration of <60 IU/l, was observed in 25%
of asymptomatic individuals.12 LSA is also associated
with metabolic syndrome (MetS), a cluster of cardiovas-
cular risk factors, and diabetes.12 13 However, obesity is
thought to be the strongest predictor of LSA in the
asymptomatic general population.12
In the last two decades, there has been a marked
increase in the prevalence of non-alcoholic fatty liver
disease (NAFLD) worldwide, along with an obesity pan-
demic.14 15 NAFLD often progresses to a more severe
condition, non-alcoholic steatohepatitis (NASH) and
increased hepatic ﬁbrosis is a signiﬁcant histological
feature of advanced NASH. NAFLD is considered to be a
hepatic manifestation of MetS and insulin resistance,14–18
which suggests that NAFLD consists of a wide spectrum of
cardiometabolic diseases. It is also possible that NAFLD
may reﬂect more pronounced insulin resistance com-
pared with MetS in certain clinical settings, including in
individuals without diabetes or obesity.17 19 20 In this
context, we hypothesised that LSA may be associated with
NAFLD independently of MetS, type 2 diabetes, and even
obesity. The aim of this study was to test this hypothesis
and to investigate the clinical relevance of LSA, which is
often observed in clinical practice. Therefore, we exam-
ined the associations among serum amylase, cardiometa-
bolic risk factors, NAFLD, hepatic ﬁbrosis, MetS and
diabetes in a cross-sectional study of asymptomatic adults.
METHODS
Protocol and subjects
The present report represents a series of observational
studies performed in collaboration with Josai University,
Sakado, Japan and Social Insurance Omiya General
Hospital that have been conducted to elucidate the rela-
tionships between lifestyle-related diseases and cardiome-
tabolic risk factors. We recruited, at random, 2472
asymptomatic subjects aged 30–79 years who underwent
thorough annual medical check-ups, in which the sub-
jects underwent a more extensive array of clinical tests
than would be performed in routine check-ups, at the
Social Insurance Omiya General Hospital, Saitama,
Japan, between April 2009 and March 2010. The protocol
was approved by The Ethics Committee of Josai
University and the Council of the Hospital, and informed
consent was obtained from all participants.
The exclusion criteria and a ﬂow chart summarising
subject disposition are shown in online supplementary
ﬁgure S1. To exclude subjects with latent conditions
likely to adversely affect the results, we excluded those
with C reactive protein ≥10.0 mg/l, estimated glomerular
ﬁltration rate (eGFR) ≤35 ml/min/1.73 m2, serum
amylase ≤30 IU/l (the lower ﬁfth percentile in an earlier
study12) or ≥200 IU/l based on previous reports,21 22 as
well as subjects suspected of having cancer. In the current
analysis, to investigate the potential relationship between
serum amylase and cardiometabolic features, including
NAFLD, we included subjects with a wider range of
serum amylase levels than the current reference ranges.
Subjects completed a questionnaire recording lifestyle
factors, including habitual alcohol consumption, which
was classiﬁed in terms of the frequency (none, occasional
and daily) and the amount of ethanol consumed per day
(<20, 20–39, 40–59 or ≥60). Subjects who habitually con-
sumed ≥20 g ethanol/day were excluded from the study.
Subjects positive for hepatic B virus surface antigen were
also excluded. Hepatic C virus infection was not mea-
sured in this study. We also excluded subjects with other
active liver diseases not examined, by excluded those with
elevated serum liver enzyme levels (approximately
3 times the upper limit of normal): alanine aminotrans-
ferase (ALT) ≥150 IU/ml, aspartate aminotransferase
(AST) ≥150 IU/ml or γ-glutamyltransferase (GGT)
≥150 IU/ml. Consequently, a total of 1475 individuals
were included in this study.
Laboratory measurements
Laboratory and anthropometric tests, and an abdominal
ultrasound were performed in the early morning after an
overnight fast. Serum parameters were measured using
an AutoAnalyzer (Hitachi, Tokyo, Japan). The serum
amylase level was measured using an enzymatic method
(L-type Amylase; Wako, Tokyo, Japan) with a detection
limit of 1.7 IU/l, and a run-to-run coefﬁcient of variation
of <5%.
Abdominal ultrasound for the detection of fatty liver
was carried out by registered medical sonographers who
only work at Social Insurance Omiya General Hospital.
The sonographers were blinded to the subjects’ data.
Fatty liver, which was determined by comparing liver
echogenicity with that of the renal cortex,23 was deﬁned
as NAFLD. Additionally, the severity of NAFLD was
graded into three categories: mild NAFLD, a slight
increase in liver echogenicity with normal visualisation of
the diaphragm and the portal veins; moderate NAFLD, a
moderate increase in liver echogenicity with slightly
impaired visualisation of the diaphragm and the portal
veins; and severe NAFLD, a substantial increase in liver
echogenicity with poor or no visualisation of the dia-
phragm and the portal veins.24 25 In a previous study, the
ultrasonographic steatosis score determined using these
grades was highly correlated with the histological grade
of steatosis (r=0.80, p<0.001), but not with inﬂammatory
activity (r=0.10) or ﬁbrosis score (r=0.19).25 Therefore,
the grade of NAFLD in this study probably reﬂects overall
hepatic fat accumulation, rather than the severity of ﬁbro-
sis. Since it is possible that mild NAFLD could include a
normal liver, we deﬁned overt NAFLD as moderate or
severe NAFLD. We also examined the ﬁndings of gall-
stones, cholecystectomy and splenomegaly, which was
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deﬁned as a spleen index (calculated as the long dimen-
sion×short dimension on splenotomogram) ≥30.26 27
The liver ﬁbrosis scores, the AST/ALTratio28 and FIB-4
were calculated in all patients, using a previously pub-
lished formula:
FIB-4=age (years)×AST/platelet count (109/l)×ALT1/2).29
The diagnosis of MetS was based on the Adult Treatment
Panel-III criteria30 with the following cut-off limits: (1) sys-
tolic blood pressure ≥130 mmHg or diastolic blood pres-
sure ≥85 mmHg; (2) triglyceride ≥150 mg/dl; (3)
high-density lipoprotein-cholesterol <40 mg/dl for men
and <50 mg/dl for women; (4) fasting plasma glucose
≥100 mg/dl and (5) waist circumference (WC) ≥90 cm for
men and ≥80 cm for women. Subjects meeting three or
more of these criteria, including treatment for any of these
disorders, were deﬁned as having MetS. Diabetes was
deﬁned as fasting plasma glucose ≥126 mg/dl or glycosy-
lated haemoglobin (HbA1c) ≥6.5% (by the National
Glycoprotein Standardization Program (NGSP)) according
to the American Diabetes Association criteria,31 or treat-
ment with oral hypoglycaemic drugs or insulin. HbA1c
( Japan Diabetes Society ( JDS)) was converted to HbA1c
(NGSP) units using the ofﬁcially certiﬁed formula:
HbA1c (NGSP) (%)=1.02×JDS (%)+0.25%.32
Since serum amylase can be affected by kidney func-
tion because of its excretion by the kidney,4 5 eGFR was
considered as a confounding factor and was calculated
using the following equation for Japanese subjects:33
eGFR (ml/min/1.73 m2)=194×serum Cr–1.094×age–0.287
(if female)×0.739. Here, Cr=serum creatine concentra-
tion (mg/dl).
Statistical analysis
Data are expressed as the mean ±SD or median (IR).
Subjects were divided into quartiles according to serum
amylase levels, where Q1 is the highest quartile and Q4
is the lowest quartile. p Values for continuous variables
were determined using analysis of variance or the
Mann-Whitney U test, and for categorical variables using
the χ2 test. Highly skewed values (ALT, AST, GGT and tri-
glyceride) were log-transformed before analysis. Subjects
were also stratiﬁed into four groups according to the
grade of NAFLD (ie, normal, mild, moderate and severe
NAFLD). Multivariate logistic regression models were
used to examine the associations of quartiles (Q2–4) of
serum amylase with any-grade NAFLD (NAFLD-AG),
and with overt NAFLD relative to Q1, controlling for
relevant confounding factors, including MetS, diabetes
and body mass index (BMI) or WC. To elucidate any
association between LSA and NAFLD, we examined the
associations between LSA and NAFLD-AG, and between
LSA and overt NAFLD. This analysis yielded OR and
95% CI. Tests for linear trends (p for trend) were calcu-
lated by treating the quartiles as a continuous variable
(ie, 1–4), and the same model analysis was conducted.
Statistical analyses were performed using SPSS software
V.18.0 (SPSS-IBM, Chicago, Illinois, USA) and Statview
V.5.0 (SAS Institute, Cary, North Carolina, USA). Values
of p<0.05 were considered to be statistically signiﬁcant.
RESULTS
The clinical characteristics of the subjects according to
the quartile of serum amylase are shown in table 1. The
mean and median values of most clinical parameters,
including platelet count and eGFR, increased signiﬁ-
cantly as serum amylase decreased, although there was a
signiﬁcant trend for subjects with lower amylase levels to
be younger. No signiﬁcant trend in HbA1c was observed
against quartiles of serum amylase. The prevalence of
NAFLD-AG and overt NAFLD increased signiﬁcantly,
from 22.5% to 42.4% and from 9.2% to 24%, respect-
ively, from the highest (Q1) to the lowest serum amylase
quartile (Q4). There were no signiﬁcant differences in
the prevalence rates of gallstones, cholecystectomy or
splenomegaly between quartiles, possibly because of the
small numbers of subjects with these features, although
the rates of cholecystectomy and splenomegaly were
higher in Q4 compared with the other quartiles.
Log-transformed serum ALT and GGT increased signiﬁ-
cantly, whereas the AST/ALT ratio and FIB-4 decreased
signiﬁcantly with decreasing serum amylase quartile.
When subjects were stratiﬁed according to NAFLD
grade, serum amylase decreased signiﬁcantly with advan-
cing grade of NAFLD (ﬁgure 1). When subjects were
further stratiﬁed according to sex, there was no signiﬁ-
cant difference between men and women. However,
when the subjects were stratiﬁed according to high or low
BMI (ﬁgure 2), serum amylase levels were signiﬁcantly
lower in overweight/obese subjects (BMI ≥25 kg/m2,
mean±SD BMI, 27.3±2.3 kg/m2, n=1121) than in lean
subjects (BMI<25 kg/m2, mean±SD BMI, 21.6±2 kg/m2,
n=354). Serum amylase levels in lean subjects decreased
signiﬁcantly with advancing grade of NAFLD, whereas
those in obese subjects did not. Signiﬁcant differences
between lean and obese subjects were only observed in
subjects with a normal liver or mild NAFLD. We did
not conduct an analysis by further stratiﬁcation according
to MetS or diabetes because of the small proportion of
subjects (both, <10%).
Multiple logistic regression analysis showed that, com-
pared with the highest quartile of serum amylase
(≥90 IU/l, Q1), the lowest quartile (<60 IU/l, Q4) was sig-
niﬁcantly associated with NAFLD-AG even after adjusting
for confounders plus MetS or diabetes (table 2, Models 4
and 5). In these conditions, MetS (OR 3.66, 95% CI 2.37
to 5.65) and diabetes (OR 1.96, 95% CI 1.25 to3.05) were
signiﬁcantly associated with Q4 of serum amylase (data
not shown). However, these associations were markedly
attenuated and were no longer statistically signiﬁcant after
adjusting for clinical confounders plus BMI or WC
(Models 6 and 7), although there was a trend towards an
association among the quartiles of serum amylase.
When we excluded subjects with mild NAFLD (n=242)
and repeated the analysis (table 3), we detected stronger
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Table 1 Characteristics of subjects stratified according to quartiles of serum amylase
Total Q1 (highest) Q2 Q3 Q4 (lowest) p Value
n 1475 369 371 381 354
Age (years) 55.1±12.2 58.4±11.8 56.4±12.2 52.9±11.7 52.7±12.0 <0.0001
Men, n (%) 747 (50.6) 178 (48.2) 176 (47.4) 205 (53.8) 188 (53.1) 0.19
BMI (kg/m2) 23.0±3.2 21.9±2.7 22.6±3.2 23.3±3.1 24.1±3.4 <0.0001
WC (cm) 80.8±8.9 78.2±8.3 79.9±8.8 81.8±8.8 83.2±9.1 <0.0001
Systolic blood pressure (mm Hg) 120±18.9 119±18.5 119±18.7 120±18.9 123±19.1 0.007
Diastolic blood pressure (mm Hg) 74.1±12.6 72.6±12.2 73.1±11.9 74.5±13.4 76.1±12.4 0.0009
Platelet count (109/l) 235±53.4 228±53.8 235±53.1 237±51.1 241±55.2 0.01
ALT (IU/l) 18 (14–25) 18 (14–23) 17 (14–23) 18 (14–25) 19 (14–29) <0.0001
AST (IU/l) 20 (17–24) 21 (19–25) 20 (17–24) 19 (17–23) 20 (17–24) 0.04
AST/ALT 1.15±0.36 1.24±0.35 1.20±0.37 1.12±0.33 1.04±0.35 <0.0001
FIB-4 1.13 (0.82–1.52) 1.33 (0.98–1.76) 1.20 (0.89–1.59) 1.05 (0.76–1.38) 0.98 (0.70–1.36) <0.0001
GGT (IU/l) 22 (16–33) 20 (15–31) 20 (16–30) 23 (16–34) 24 (17–38) 0.0009
C reactive protein 0.4 (0.3–0.8) 0.3 (0.3–0.63) 0.4 (0.3–0.8) 0.4 (0.3–0.8) 0.5 (0.3–1.1) <0.0001
Amylase (IU/l) (range) 77.3±24.9 (30–200) 110±22.0 (90–200) 81.3±4.7 (74–89) 66.6±4.1 (60–73) 50.3±7.0 (30–59) –
Triglyceride (mg/dl) 88 (64–128) 83 (63–121) 84 (62–123) 88 (65–128) 100 (65–143) 0.001
HDL cholesterol (mg/dl) 61.2±15.0 64.2±15.4 62.6±14.8 59.8±14.6 58.3±14.5 <0.0001
Fasting plasma glucose (mg/dl) 99.6±16.7 97.5±13.4 97.4±11.4 101±19.4 103±20.4 <0.0001
HbA1c (NGSP) (%) 5.7±0.6 5.7±0.5 5.7±0.4 5.7±0.6 5.8±0.7 0.14
eGFR (ml/min/1.73 m2) 75.0±13.9 71.0±14.3 74.3±12.9 76.0±14.2 78.7±13.1 <0.0001
ATP-III-metabolic syndrome, n (%) 139 (9.4) 16 (4.3) 23 (6.2) 47 (12.3) 53 (15.0) <0.0001
Diabetes, n (%) 114 (7.7) 19 (5.1) 17 (4.6) 34 (8.9) 44 (12.4) 0.0002
NAFLD of all grades, n (%) 463 (31.4) 83 (22.5) 97 (26.1) 133 (34.9) 150 (42.4) <0.0001
Moderate-to-severe NAFLD, n (%) 221 (15.0) 34 (9.2) 42 (11.3) 60 (15.7) 85 (24.0) <0.0001
Gallstones, n (%) 81 (5.5) 21 (5.7) 20 (5.4) 24 (6.3) 16 (5.2) 0.76
Cholecystectomy, n (%) 23 (1.6) 5 (1.4) 3 (0.8) 5 (1.3) 10 (2.8) 0.15
Splenomegaly, n (%) 9 (0.6) 1 (0.3) 1 (0.3) 0 7 (2.0) –*
Medical history of
Cardiovascular diseases, n (%) 55 (3.7) 11 (3.0) 20 (5.4) 11 (2.9) 13 (3.7) 0.24
Stroke, n (%) 26 (1.8) 12 (3.3) 6 (1.6) 4 (1.1) 4 (1.1) 0.08
Medications for
Hypertension, n (%) 237 (16.1) 64 (17.3) 47 (12.7) 67 (17.6) 59 (16.7) 0.22
Hypercholesterolaemia, n (%) 177 (12.0) 56 (15.2) 43 (11.6) 34 (8.9) 44 (12.4) 0.07
Diabetes, n (%) 56 (3.8) 12 (3.3) 12 (3.2) 15 (3.9) 17 (4.8) 0.65
Current smoker, n (%) 273 (18.5) 40 (10.8) 50 (13.5) 86 (22.6) 97 (27.4) <0.0001
Everyday alcohol consumers, n (%) 229 (15.5) 51 (13.8) 59 (15.9) 66 (17.3) 53 (15.0) 0.61
Regular exercise, n (%) 507 (34.4) 144 (39.0) 135 (36.4) 125 (32.9) 103 (29.1) 0.03
Data are means±SD and medians (IR). p Values for continuous variables and categorical variables were determined by analysis of variance and the χ2 test, respectively. Regular exercise:
≥30 min exercise per session at least twice a week.
*Statistical analysis was not performed because of the small number of subjects with splenomegaly.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ-glutamyltransferase; HDL, high-density lipoprotein; NAFLD, non-alcoholic fatty liver disease;
NGSP, National Glycoprotein Standardization Program; WC, waist circumference.
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signiﬁcant associations between Q4 and overt NAFLD.
These associations were also moderately attenuated after
additional adjustment for BMI or WC, but they
remained statistically signiﬁcant (Models 6 and 7). In
this condition, BMI (OR 1.65, 95% CI 1.51 to 1.80) and
WC (OR 1.21, 95% CI 1.17 to 1.25) were signiﬁcantly
associated with overt NAFLD (data not shown).
DISCUSSION
For the last few decades, NAFLD has been considered as
a manifestation of MetS and insulin resistance.14–18 In
this context, the present study showed that LSA was sig-
niﬁcantly associated with NAFLD-AG in asymptomatic
adults, independent of MetS, diabetes and sex.
Furthermore, LSA may be indicative of overt NAFLD,
that is, moderate or severe NAFLD, independent of
obesity. These ﬁndings are not inconsistent because
NAFLD may reﬂect insulin resistance, more so than
MetS, in individuals without diabetes or obesity.17 19 20
This study provided evidence that NAFLD can occur
in lean individuals, who accounted for 37.8% (62/104)
of subjects with moderate NAFLD and 19.3% (11/57) of
subjects with severe NAFLD (ﬁgure 2). This is consistent
with the results of multivariate logistic analysis, where
there was a signiﬁcant trend for NAFLD against quartiles
of serum amylase, and the signiﬁcant association
between the lowest quartile of serum amylase and
NAFLD remained after adjusting for BMI and WC
(tables 2 and 3).
Potential mechanisms of the inverse relationship between
serum amylase and NAFLD
We found no signiﬁcant difference in serum amylase
levels between lean and obese subjects with overt
NAFLD, suggesting that the effects of obesity on serum
amylase are apparent in subjects with a normal liver or
with mild NAFLD, but not in subjects with overt NAFLD.
Several studies have shown that NAFLD occurs in non-
obese people, although the prevalence of NAFLD in
non-obese subjects is lower than that in obese sub-
jects.19 20 34 Therefore, other than obesity, factors not
examined in this study might also explain the association
between LSA and NAFLD. Insulin resistance and
obesity-related hormones, such as leptin, may be poten-
tial factors, because insulin resistance and energy imbal-
ance are common pathophysiological ﬁndings in obese
individuals.17 35 Indeed, obesity plus insulin resistance is
more closely associated with metabolic abnormalities
and NAFLD than is obesity without insulin resistance.17
Hyperinsulinaemia caused by insulin resistance stimu-
lates de novo lipogenesis in the liver through sterol regu-
latory element binding protein-1c (SREBP-1c),36
irrespective of the inﬂux of fatty acid from a meal and
lipolysis in adipose tissues. Additionally, we recently
reported a latent association between LSA and insulin
resistance in a small study of asymptomatic middle-aged
adults,37 supporting the hypothesis that LSA may be
associated with NAFLD, at least in part through insulin
resistance. However, because insulin resistance, as deter-
mined by the homeostasis model assessment of insulin
resistance, for example, was not examined in this study,
further large epidemiological studies evaluating insulin
resistance are needed to conﬁrm the current hypothesis.
As another explanation for the inverse relationship
between serum amylase and NAFLD, systemic ectopic fat
deposition in organs including the pancreas (ie, fatty
pancreas) might contribute to the observed associations.
This is because intrapancreatic fat, particularly intralobu-
lar pancreatic fat, was reported to be associated with
Figure 1 Serum amylase levels according to the grade of
non-alcoholic fatty liver disease (NAFLD) and sex. Serum
amylase levels decreased significantly with advancing grade
of NAFLD in both sexes (analysis of variance (ANOVA), both
p=0.0001). There was no significant difference between men
and women (two-way ANOVA, p=0.45). *Number of subjects
in each group. Bars represent SEs.
Figure 2 Serum amylase levels according to the grade of
non-alcoholic fatty liver disease (NAFLD) and obesity. Obesity
was defined as body mass index ≥25 kg/m2. Serum amylase
levels decreased significantly with advancing grade of NAFLD
in lean subjects (analysis of variance (ANOVA), p=0.01), but
not in obese subjects (p=0.33). An overall significant
difference was observed between lean and obese subjects
(two-way ANOVA, p=0.03). *Number of subjects in each
group; †p=0.0001 and ‡p=0.02 for lean versus obese subjects
(Mann-Whitney U test). Bars represent SEs.
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NAFLD and MetS.38 39 An animal study showed that
obese mice had a heavier pancreas and more intrapan-
creatic fat.40 Therefore, systemic fat deposits in multiple
organs may be a common cause underlying the associ-
ation between NAFLD and overall pancreatic dysfunc-
tion, which may result in impaired exocrine function,
characterised as LSA.
Gene polymorphisms of patatin-like phospholipase
domain containing 3 (PNPLA3) may also contribute to
the strength of these associations. For example, a
common variant of the PNPLA3 gene (rs738409) was
reported to be associated with increased hepatic fat
content (ie, NAFLD).41 In the mouse liver, adiponutrin/
PNPLA3 gene expression is under the direct transcrip-
tional control of SREBP-1c, in response to insulin.42
Serum amyalse and glucose metabolism
The prevalence of diabetes increased with decreasing
serum amylase quartile in this study. However, similar to
an earlier study,12 HbA1c was not associated with LSA,
probably because most subjects in the lowest quartile of
serum amylase in this study had no or only mild insulin
resistance or mild hyperinsulinaemia, which is likely
compensated for and results in euglycaemia or mild
hyperglycaemia. In such conditions, fasting plasma
glucose would increase linearly, as observed in table 1,
in response to insulin resistance, particularly in the early
stage of diabetes.43 44
Serum amyalse and hepatic fibrosis
To date, some markers have been considered for screen-
ing for NAFLD and mild hepatic ﬁbrosis.45–47 In this
study, while the AST/ALT ratio and Fib-4 decreased sig-
niﬁcantly with the decreasing quartile of serum amylase,
the platelet count increased (table 1). Consequently,
hepatic ﬁbrosis is unlikely to be associated with NAFLD
in this study. A plausible explanation is that this study
mostly consisted of non-obese individuals, with a small
proportion having MetS and diabetes, resulting in a
lower likelihood of advanced hepatic ﬁbrosis and NASH.
In fact, the estimated prevalence of NASH in this study
is quite low when we compare it with the prevalence of
NASH in a nationwide study in Japan. It was reported
that approximately 20–25% of patients with diabetes had
NAFLD, a population in which the prevalence of NASH
might be 30–40%.48 Therefore, the estimated prevalence
Table 2 ORs for NAFLD-AG according to serum amylase quartiles
Serum amylase quartiles Q1 (highest) Q2 Q3 Q4 (lowest) p for trend
N 369 371 381 354
Model 1 1 1.22 (0.87 to 1.71) 1.85 (1.34 to 2.55) 2.53 (1.84 to 3.50) <0.0001
Model 2 1 1.28 (0.91 to 1.81) 1.96 (1.39 to 2.74) 2.74 (1.95 to 3.85) <0.0001
Model 3 1 1.35 (0.93 to 1.97) 2.03 (1.41 to 2.94) 2.41 (1.66 to 3.51) <0.0001
Model 4 1 1.25 (0.86 to 1.82) 1.83 (1.26 to 2.65) 2.18 (1.49 to 3.18) <0.0001
Model 5 1 1.31 (0.90 to 1.90) 2.00 (1.39 to 2.89) 2.36 (1.62 to 3.44) <0.0001
Model 6 1 0.99 (0.66 to 1.49) 1.34 (0.89 to 2.01) 1.42 (0.94 to 2.15) 0.04
Model 7 1 1.02 (0.68 to 1.53) 1.30 (0.87 to 1.94) 1.49 (0.99 to 2.24) 0.03
Model 1: unadjusted.
Model 2: adjusted for age, sex and current smoking (vs non-smokers).
Model 3: Model 2 plus adjustment for log-transformed ALT, regular exercise (vs infrequent exercise), daily alcohol consumption (vs infrequent/
no alcohol consumption), eGFR, history of heart diseases and stroke and medications for hypertension, diabetes and dyslipidaemia.
Model 4: Model 3 plus adjustment for diabetes, but excluding medications for hypertension, diabetes and dyslipidaemia.
Model 5: Model 3 plus adjustment for metabolic syndrome, but excluding medications for hypertension, diabetes and dyslipidaemia.
Model 6: Model 3 plus adjustment for BMI.
Model 7: Model 3 plus adjustment for WC.
ALT, alanine aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; NAFLD, non-alcoholic fatty liver disease;
WC, waist circumference.
Table 3 ORs of each serum amylase for NAFLD of moderate or severe grade
Serum amylase quartiles Q1 (highest) Q2 Q3 Q4 (lowest) p for trend
N* 320 316 308 289
Model 1 1 1.29 (0.80 to 2.09) 2.04 (1.29 to 3.20) 3.51 (2.27 to 5.42) <0.0001
Model 2 1 1.36 (0.83 to 2.22) 2.14 (1.33 to 3.44) 3.81 (2.40 to 6.05) <0.0001
Model 3 1 1.61 (0.91 to 2.86) 2.32 (1.32 to 4.07) 3.45 (1.99 to 6.00) <0.0001
Model 4 1 1.48 (0.84 to 2.64) 2.11 (1.19 to 3.73) 2.97 (1.70 to 5.20) <0.0001
Model 5 1 1.56 (0.89 to 2.75) 2.32 (1.33 to 4.04) 3.26 (1.88 to 5.66) <0.0001
Model 6 1 1.05 (0.54 to 2.03) 1.44 (0.76 to 2.72) 2.01 (1.07 to 3.78) 0.01
Model 7 1 1.06 (0.55 to 2.05) 1.37 (0.73 to 2.59) 2.06 (1.09 to 3.87) 0.01
*Subjects with mild NAFLD (n=242) were excluded from this analysis. Models 1–7 are the same as those in table 2.
NAFLD, non-alcoholic fatty liver disease.
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of NASH might be less than 1% of all of the subjects in
this study. In addition, the fact that more than half of
the subjects in this study had repeatedly undergone
detailed medical check-ups may also contribute to the
lower prevalence of NASH, because repeated check-ups
may promote consciousness of healthcare and favour-
able lifestyles.
LIMITATIONS
Several limitations should be mentioned. First, NAFLD
was diagnosed by ultrasound rather than by histological
examination, the gold standard technique for the diagno-
sis of NAFLD. Thus, NAFLD and the degree of hepatic
ﬁbrosis could be inaccurately evaluated, particularly in
the early stages. In earlier studies, ultrasonography had a
sensitivity of 60–94% and a speciﬁcity of 66–95% for
detecting fatty liver.24 49 However, its sensitivity is reduced
in subjects with a small amount of fat (<30%), such as
those with mild NAFLD or advanced ﬁbrosis.14 To
improve the accuracy of detecting and grading of
NAFLD, the use of other imaging modalities might be
needed, such as MRI and MR spectroscopy, which were
reported to provide useful quantitative data in earlier
studies.24 50
Second, hepatitis C virus infection was not measured in
this study. However, the prevalence of hepatitis C infec-
tion was reported to be 1.5–2.3% in Japan.51 Low preva-
lence rates of hepatitis C (<1.5%) were also recently
reported in Asian-Paciﬁc, tropical Latin American and
North American countries.52 Therefore, hepatitis C infec-
tion is unlikely to profoundly modify the association
between LSA and NAFLD in this study, although hepatitis
C infection can contribute to the development of
NAFLD.53 It is also possible that individuals with primary
biliary cirrhosis, autoimmune hepatitis or other forms of
liver dysfunction (eg, haemochromatosis and Wilson
disease) were included in the present study, even though
we excluded subjects with elevated hepatic enzymes
(≥150 IU/ml). However, the prevalence of these diseases
is quite low in the general population54–56
Third, because of the cross-sectional nature of the
study, we could not determine the cause–effect relation-
ship between LSA and NAFLD. However, in a previous
retrospective study,12 subjects with LSA at baseline were
more likely to develop MetS-related metabolic abnormal-
ities 5 years later. Longitudinal prospective studies or clin-
ical intervention trials are needed to elucidate the
causality of the associations reported here.
Finally, the clinical relevance of measuring serum
amylase remains unclear. The current results suggest that
LSA is likely to detect overt NAFLD, but not NASH,
which is the most important hepatic disorder. However,
from the cardiometabolic perspective, even simple stea-
tosis may be important, particularly in non-obese people,
because steatosis may be more strongly associated with
insulin resistance than is obesity.17 19 20 Currently, serum
amylase is rarely considered in clinical practice, except in
certain situations, such as suspected pancreatitis.
Therefore, numerous clinical and animal studies are
needed to validate and conﬁrm the clinical relevance of
measuring serum amylase before it can be introduced
into primary care for the detection of cardiometabolic
diseases and NAFLD.
CONCLUSION
Our results suggest that LSA may be associated with
NAFLD, particularly moderate or severe NAFLD, in
asymptomatic adults. This association was independent
of MetS, diabetes and obesity. Further studies are
needed to conﬁrm the observed associations, and to
explore the clinical relevance of LSA.
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